Author:
Bian Chengrong,Liu Shuzhen,Liu Na,Zhang Guangzhou,Xing Li,Song Yingwei,Duan Yueqiang,Gu Hongjing,Zhou Ya,Zhang Peirui,Li Zhiwei,Zhang Keming,Wang Zhaohai,Zhang Shaogeng,Wang Xiliang,Yang Penghui
Reference27 articles.
1. Generation and characterization of a cold-adapted attenuated live H3N2 subtype influenza virus vaccine candidate;An;Chin. Med. J.,2009
2. Misreading of termination codons in eukaryotes by natural nonsense suppressor tRNAs;Beier;Nucleic Acids Res.,2001
3. A genetically engineered influenza A virus with ras-dependent oncolytic properties;Bergmann;Cancer Res.,2001
4. Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children;Bernstein;Pediatr. Infect. Dis. J.,2012
5. Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease;Castilow;Immunol. Res.,2007